Eli Lilly Shows Strong Growth Prospects
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy LLY?
Source: Fool
- Market Leadership: Eli Lilly has established itself as a leader in the rapidly growing GLP-1 drug market, with strong assets like Mounjaro and Zepbound driving significant growth in recent years, showcasing its competitive edge in the biopharmaceutical sector.
- Analyst Optimism: The current consensus price target for Eli Lilly's stock is $1,215, indicating a potential upside of approximately 26% for investors buying at the current price of $960, with 25 out of 30 analysts rating the stock as a buy, reflecting strong market confidence in its future performance.
- Attractive Valuation: Although Eli Lilly's price-to-earnings ratio is not cheap, its valuation has become more attractive due to a decline in stock price coupled with rising earnings, with sales projected to grow from $28.5 billion in 2022 to $65.2 billion by 2025, and profits tripling to $20.6 billion during this period.
- Long-Term Investment Potential: With excellent fundamentals and growth prospects, Eli Lilly's stock is expected to rally this year and potentially surpass the $1,000 mark, and in the long run, it could rise even higher, making it an excellent long-term holding choice.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 988.870
Low
950.00
Averages
1192
High
1500
Current: 988.870
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Reports Skyrocketing Q1 Profits Driven by GLP-1 Sales
- Revenue Surge: Eli Lilly's Q1 revenue soared 56% year-over-year to $19.8 billion, primarily driven by its blockbuster GLP-1 weight loss drugs, demonstrating robust market demand despite a 13% price decline offset by a 65% volume increase.
- Net Income Spike: Adjusted net income skyrocketed 155% to $7.7 billion, translating to $8.55 per share, significantly surpassing Wall Street's estimate of $6.79, reflecting the company's strong performance in the weight loss drug sector.
- Sales Growth Drivers: Sales of GLP-1 drugs Mounjaro and Zepbound surged 125% and 80%, reaching $8.7 billion and $4.2 billion respectively, becoming key growth drivers that further solidify the company's market leadership.
- Optimistic Outlook: Eli Lilly raised its 2023 revenue and adjusted EPS guidance to $82 billion to $85 billion and $35.50 to $37, indicating confidence in future growth, particularly with the newly launched GLP-1 pill Foundayo expected to expand market share.
See More
Health Canada Approves Lilly's Kisunla™ (Donanemab) as a New Treatment for Early Alzheimer's Disease
Health Canada Authorization: Health Canada has authorized the use of Lilly's drug, known as Skysunla (donanemab), for the treatment of early Alzheimer's disease.
New Treatment Option: This approval introduces a new therapeutic option aimed at addressing the needs of patients diagnosed with early-stage Alzheimer's.
See More
Market Update: Stocks Rise as Oil Prices Fall
- War Ending Anticipation: Stock futures rose as Axios reported that the Iran war may soon end, with the S&P 500 and Nasdaq hitting record highs yesterday, reflecting investor optimism about economic recovery prospects.
- Aerospace Stock Surge: Travel and aerospace stocks are poised to benefit if the war concludes, with Boeing shares up about 4% and Delta Airlines rising 6%, indicating strong market expectations for a rebound in air travel demand.
- Optical Technology Deal: Corning and Nvidia announced a significant deal, with Corning set to build three new plants, increasing its domestic optical manufacturing capacity tenfold, leading to a 15% surge in Corning's stock, highlighting strong demand for optical technology over copper.
- AI Market Growth: AMD's second-quarter guidance exceeded expectations, predicting the server CPU market will reach $120 billion by 2030, with AMD shares soaring 15%, indicating sustained growth in the semiconductor industry driven by AI technology.
See More
Eli Lilly Commits Additional $4.5 Billion Investment in Indiana
- Investment Expansion: Eli Lilly announced an additional $4.5 billion investment across its three Indiana sites, bringing its total capital expansion commitments in the state since 2020 to over $21 billion, demonstrating the company's long-term commitment and confidence in the region.
- Economic Boost: This investment is expected to further drive economic growth in Indiana and create numerous job opportunities, positively impacting local communities and enhancing the company's competitiveness in the biopharmaceutical industry.
- Production Capacity Enhancement: The funding will bolster Eli Lilly's production capabilities in Indiana, supporting the expansion of its product lines, particularly in the biopharmaceutical sector, to meet the growing market demand.
- Strategic Positioning: This investment is part of Eli Lilly's strategic plan to solidify its leadership position in the U.S. market through continuous capital infusion while responding to global demand for innovative medications.
See More
India's Offshore Tech Centers Expected to Generate $98.4 Billion in Revenue
- Revenue Growth Forecast: According to a report by Nasscom and Zinnov, India's offshore technology centers are expected to generate $98.4 billion in revenue for fiscal 2026, nearing earlier projections for 2030, indicating a trend of global firms accelerating their outsourcing to India due to rising costs and geopolitical uncertainties.
- High-Value Function Transformation: Companies such as JPMorgan Chase, McDonald's, and Nvidia are increasingly leveraging Global Capability Centers (GCCs) to support high-value functions like finance, software development, and R&D, demonstrating India's evolving role in global outsourcing beyond low-cost back-office support.
- AI-Driven Expansion Capability: With a large AI-ready workforce and faster-to-scale operating models, coupled with supportive tax policies, firms are able to expand these high-value functions much faster than before, further solidifying India's competitive position in the global market.
- North American Market Dominance: The report highlights that North American firms remain the main engine of India's GCC expansion, accounting for two-thirds of new setups, as many companies relocate work to India to access talent, reflecting strong demand for the Indian market.
See More
Wegovy Pill Prescriptions Exceed 2 Million Since Launch
- Prescription Surge: Since its January launch, Wegovy pill prescriptions have surpassed 2 million, with 1.3 million in Q1 alone, indicating robust market demand that enhances the company's competitive edge in the obesity drug sector.
- Upgraded Sales Outlook: Despite ongoing pricing pressures, Novo Nordisk raised its 2026 sales and operating profit outlook to a decline of 4%-12%, reflecting strong demand for Wegovy and a recovery in market confidence.
- Strong Financial Performance: In Q1, adjusted operating profit reached 32.9 billion Danish kroner (approximately $5 billion), down 15% year-over-year, yet sales rose by 32% to 96.8 billion kroner, showcasing the strong performance of obesity care products.
- Intensifying Market Competition: Facing pressure from Eli Lilly, Novo Nordisk is aggressively marketing Wegovy through lower pricing and advertising campaigns to attract new users, ensuring its leadership position in the oral GLP-1 drug market.
See More
Eli Lilly Reports Skyrocketing Q1 Profits Driven by GLP-1 Sales
- Revenue Surge: Eli Lilly's Q1 revenue soared 56% year-over-year to $19.8 billion, primarily driven by its blockbuster GLP-1 weight loss drugs, demonstrating robust market demand despite a 13% price decline offset by a 65% volume increase.
- Net Income Spike: Adjusted net income skyrocketed 155% to $7.7 billion, translating to $8.55 per share, significantly surpassing Wall Street's estimate of $6.79, reflecting the company's strong performance in the weight loss drug sector.
- Sales Growth Drivers: Sales of GLP-1 drugs Mounjaro and Zepbound surged 125% and 80%, reaching $8.7 billion and $4.2 billion respectively, becoming key growth drivers that further solidify the company's market leadership.
- Optimistic Outlook: Eli Lilly raised its 2023 revenue and adjusted EPS guidance to $82 billion to $85 billion and $35.50 to $37, indicating confidence in future growth, particularly with the newly launched GLP-1 pill Foundayo expected to expand market share.
See More
Health Canada Approves Lilly's Kisunla™ (Donanemab) as a New Treatment for Early Alzheimer's Disease
Health Canada Authorization: Health Canada has authorized the use of Lilly's drug, known as Skysunla (donanemab), for the treatment of early Alzheimer's disease.
New Treatment Option: This approval introduces a new therapeutic option aimed at addressing the needs of patients diagnosed with early-stage Alzheimer's.
See More
Market Update: Stocks Rise as Oil Prices Fall
- War Ending Anticipation: Stock futures rose as Axios reported that the Iran war may soon end, with the S&P 500 and Nasdaq hitting record highs yesterday, reflecting investor optimism about economic recovery prospects.
- Aerospace Stock Surge: Travel and aerospace stocks are poised to benefit if the war concludes, with Boeing shares up about 4% and Delta Airlines rising 6%, indicating strong market expectations for a rebound in air travel demand.
- Optical Technology Deal: Corning and Nvidia announced a significant deal, with Corning set to build three new plants, increasing its domestic optical manufacturing capacity tenfold, leading to a 15% surge in Corning's stock, highlighting strong demand for optical technology over copper.
- AI Market Growth: AMD's second-quarter guidance exceeded expectations, predicting the server CPU market will reach $120 billion by 2030, with AMD shares soaring 15%, indicating sustained growth in the semiconductor industry driven by AI technology.
See More
Eli Lilly Commits Additional $4.5 Billion Investment in Indiana
- Investment Expansion: Eli Lilly announced an additional $4.5 billion investment across its three Indiana sites, bringing its total capital expansion commitments in the state since 2020 to over $21 billion, demonstrating the company's long-term commitment and confidence in the region.
- Economic Boost: This investment is expected to further drive economic growth in Indiana and create numerous job opportunities, positively impacting local communities and enhancing the company's competitiveness in the biopharmaceutical industry.
- Production Capacity Enhancement: The funding will bolster Eli Lilly's production capabilities in Indiana, supporting the expansion of its product lines, particularly in the biopharmaceutical sector, to meet the growing market demand.
- Strategic Positioning: This investment is part of Eli Lilly's strategic plan to solidify its leadership position in the U.S. market through continuous capital infusion while responding to global demand for innovative medications.
See More
India's Offshore Tech Centers Expected to Generate $98.4 Billion in Revenue
- Revenue Growth Forecast: According to a report by Nasscom and Zinnov, India's offshore technology centers are expected to generate $98.4 billion in revenue for fiscal 2026, nearing earlier projections for 2030, indicating a trend of global firms accelerating their outsourcing to India due to rising costs and geopolitical uncertainties.
- High-Value Function Transformation: Companies such as JPMorgan Chase, McDonald's, and Nvidia are increasingly leveraging Global Capability Centers (GCCs) to support high-value functions like finance, software development, and R&D, demonstrating India's evolving role in global outsourcing beyond low-cost back-office support.
- AI-Driven Expansion Capability: With a large AI-ready workforce and faster-to-scale operating models, coupled with supportive tax policies, firms are able to expand these high-value functions much faster than before, further solidifying India's competitive position in the global market.
- North American Market Dominance: The report highlights that North American firms remain the main engine of India's GCC expansion, accounting for two-thirds of new setups, as many companies relocate work to India to access talent, reflecting strong demand for the Indian market.
See More
Wegovy Pill Prescriptions Exceed 2 Million Since Launch
- Prescription Surge: Since its January launch, Wegovy pill prescriptions have surpassed 2 million, with 1.3 million in Q1 alone, indicating robust market demand that enhances the company's competitive edge in the obesity drug sector.
- Upgraded Sales Outlook: Despite ongoing pricing pressures, Novo Nordisk raised its 2026 sales and operating profit outlook to a decline of 4%-12%, reflecting strong demand for Wegovy and a recovery in market confidence.
- Strong Financial Performance: In Q1, adjusted operating profit reached 32.9 billion Danish kroner (approximately $5 billion), down 15% year-over-year, yet sales rose by 32% to 96.8 billion kroner, showcasing the strong performance of obesity care products.
- Intensifying Market Competition: Facing pressure from Eli Lilly, Novo Nordisk is aggressively marketing Wegovy through lower pricing and advertising campaigns to attract new users, ensuring its leadership position in the oral GLP-1 drug market.
See More
